Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 121

1.

Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool.

Jongmans MC, Loeffen JL, Waanders E, Hoogerbrugge PM, Ligtenberg MJ, Kuiper RP, Hoogerbrugge N.

Eur J Med Genet. 2016 Jan 26. pii: S1769-7212(16)30008-8. doi: 10.1016/j.ejmg.2016.01.008. [Epub ahead of print]

2.

Screening for Psychosocial Risk in Dutch Families of a Child With Cancer: Reliability, Validity, and Usability of the Psychosocial Assessment Tool.

Sint Nicolaas SM, Schepers SA, Hoogerbrugge PM, Caron HN, Kaspers GJ, van den Heuvel-Eibrink MM, Grootenhuis MA, Verhaak CM.

J Pediatr Psychol. 2015 Dec 29. pii: jsv119. [Epub ahead of print]

PMID:
26715054
3.

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.

Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN, Scheijen B.

Leukemia. 2015 Dec 29. doi: 10.1038/leu.2015.359. [Epub ahead of print] No abstract available.

PMID:
26713593
4.

Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.

Yuniati L, van der Meer LT, Tijchon E, van Ingen Schenau D, van Emst L, Levers M, Palit SA, Rodenbach C, Poelmans G, Hoogerbrugge PM, Shan J, Kilberg MS, Scheijen B, van Leeuwen FN.

Oncotarget. 2015 Dec 9. doi: 10.18632/oncotarget.6519. [Epub ahead of print]

5.

Sharing decisions during diagnostic consultations; an observational study in pediatric oncology.

Wiering BM, Noordman J, Tates K, Zwaanswijk M, Elwyn G, De Bont ES, Beishuizen A, Hoogerbrugge PM, Van Dulmen S.

Patient Educ Couns. 2016 Jan;99(1):61-7. doi: 10.1016/j.pec.2015.07.026. Epub 2015 Jul 29.

PMID:
26298218
6.

Targeted Deletion of Btg1 and Btg2 Results in Homeotic Transformation of the Axial Skeleton.

Tijchon E, van Ingen Schenau D, van Opzeeland F, Tirone F, Hoogerbrugge PM, Van Leeuwen FN, Scheijen B.

PLoS One. 2015 Jul 28;10(7):e0131481. doi: 10.1371/journal.pone.0131481. eCollection 2015.

7.

Independent development of lymphoid and histiocytic malignancies from a shared early precursor.

Waanders E, Hebeda KM, Kamping EJ, Groenen PJ, Simons A, Hoischen A, Jongmans MC, Hoogerbrugge PM, van Leeuwen FN, Kuiper RP, Te Loo DM.

Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.193. [Epub ahead of print] No abstract available.

PMID:
26202925
8.

Illness cognitions and family adjustment: psychometric properties of the Illness Cognition Questionnaire for parents of a child with cancer.

Sint Nicolaas SM, Schepers SA, van den Bergh EM, Evers AW, Hoogerbrugge PM, Grootenhuis MA, Verhaak CM.

Support Care Cancer. 2016 Feb;24(2):529-37. doi: 10.1007/s00520-015-2795-5. Epub 2015 Jun 25.

9.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1.

PMID:
26033801
10.

A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.

Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW, Flucke U, van Leeuwen FN, Hoogerbrugge PM, Guchelaar HJ, te Loo DM.

Clin Cancer Res. 2015 Aug 1;21(15):3436-41. doi: 10.1158/1078-0432.CCR-14-2638. Epub 2015 Mar 31.

PMID:
25829401
11.

TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation.

Middelbeek J, Visser D, Henneman L, Kamermans A, Kuipers AJ, Hoogerbrugge PM, Jalink K, van Leeuwen FN.

Oncotarget. 2015 Apr 20;6(11):8760-76.

12.

Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents.

Kroesen M, Brok IC, Reijnen D, van Hout-Kuijer MA, Zeelenberg IS, Den Brok MH, Hoogerbrugge PM, Adema GJ.

Cancer Immunol Immunother. 2015 May;64(5):563-72. doi: 10.1007/s00262-015-1663-y. Epub 2015 Feb 17.

13.

Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.

Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI, van Leeuwen FN, Gelderblom H, Hoogerbrugge PM, Guchelaar HJ, Te Loo MW.

PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014.

14.

A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics.

van der Meer LT, Waanders E, Levers M, Venselaar H, Roeleveld D, Boos J, Lanvers C, Brüggemann RJ, Kuiper RP, Hoogerbrugge PM, van Leeuwen FN, te Loo DM.

Blood. 2014 Nov 6;124(19):3027-9. doi: 10.1182/blood-2014-06-582627. No abstract available.

15.

Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial.

Masurekar AN, Parker CA, Shanyinde M, Moorman AV, Hancock JP, Sutton R, Ancliff PJ, Morgan M, Goulden NJ, Fraser C, Hoogerbrugge PM, Revesz T, Darbyshire PJ, Krishnan S, Love SB, Saha V.

PLoS One. 2014 Oct 3;9(10):e108107. doi: 10.1371/journal.pone.0108107. eCollection 2014.

16.

HDAC inhibitors and immunotherapy; a double edged sword?

Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ.

Oncotarget. 2014 Aug 30;5(16):6558-72. Review.

17.

The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.

Masurekar A, Fong C, Hussein A, Revesz T, Hoogerbrugge PM, Love S, Ciria C, Parker C, Krishnan S, Saha V.

Blood Cancer J. 2014 Apr 25;4:e203. doi: 10.1038/bcj.2014.26. No abstract available.

18.

Self-perception and quality of life in adolescents during treatment for a primary malignant bone tumour.

van Riel CA, Meijer-van den Bergh EE, Kemps HL, Feuth T, Schreuder HW, Hoogerbrugge PM, De Groot IJ, Mavinkurve-Groothuis AM.

Eur J Oncol Nurs. 2014 Jun;18(3):267-72. doi: 10.1016/j.ejon.2014.01.005. Epub 2014 Mar 18.

PMID:
24656419
19.

Patient reported outcomes in pediatric oncology practice: suggestions for future usage by parents and pediatric oncologists.

Schepers SA, Engelen VE, Haverman L, Caron HN, Hoogerbrugge PM, Kaspers GJ, Egeler RM, Grootenhuis MA.

Pediatr Blood Cancer. 2014 Sep;61(9):1707-10. doi: 10.1002/pbc.25034. Epub 2014 Mar 20.

PMID:
24648289
20.

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk